APA (7th ed.) Citation

Eckstein, M., Erben, P., Kriegmair, M., Worst, T., & Weis, C. T. (2019). Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. European journal of cancer, 106, . https://doi.org/10.1016/j.ejca.2018.11.007

Chicago Style (17th ed.) Citation

Eckstein, Markus, Philipp Erben, Maximilian Kriegmair, Thomas Worst, and Cleo-Aron Thias Weis. "Performance of the Food and Drug Administration/EMA-approved Programmed Cell Death Ligand-1 Assays in Urothelial Carcinoma with Emphasis on Therapy Stratification for First-line Use of Atezolizumab and Pembrolizumab." European Journal of Cancer 106 (2019). https://doi.org/10.1016/j.ejca.2018.11.007.

MLA (9th ed.) Citation

Eckstein, Markus, et al. "Performance of the Food and Drug Administration/EMA-approved Programmed Cell Death Ligand-1 Assays in Urothelial Carcinoma with Emphasis on Therapy Stratification for First-line Use of Atezolizumab and Pembrolizumab." European Journal of Cancer, vol. 106, 2019, https://doi.org/10.1016/j.ejca.2018.11.007.